Bio-Techne to Highlight Advances in the Detection of Clinically Relevant Biomarkers using RNAscope Technologies at the 2025 USCAP Annual Meeting

Rhea-AI Summary

Bio-Techne (NASDAQ: TECH) announced advancements in its RNAscope technology for biomarker detection and pathology laboratory workflow improvements, to be presented at the 2025 USCAP Annual Meeting in Boston (March 22-27). The company's Advanced Cell Diagnostics brand will showcase the technology at booth #222.

During the 'RNAscope: Lightning Lunch and Learn' session on March 25, four leading pathologists will present their research:

• Dr. Rohit Mehra on TRIM63 mRNA as a marker in renal cell carcinoma
• Dr. Vikram Deshpande on albumin mRNA for liver tumors
• Dr. Brooke Howitt on point mutation detection in gynecologic tumors
• Dr. Gregory Bean on mRNA detection from CRTC1/3::MAML2 translocations

The presentations will demonstrate RNAscope's potential to improve performance over existing methods and reduce time to results in detecting clinically relevant biomarkers, including secreted proteins, point mutations, and chromosomal translocations.

Positive

• RNAscope technology demonstrates superior performance in biomarker detection compared to traditional methods
• Technology shows potential for improved diagnostic accuracy in multiple cancer types
• Validation of technology by leading pathologists from prestigious institutions

Negative

• Product is currently to research use only, not approved for diagnostic procedures

News Market Reaction

+0.76%

1 alert

+0.76% News Effect

On the day this news was published, TECH gained 0.76%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

MINNEAPOLIS, March 24, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced further advancements in its ongoing strategy to bring translational discoveries to patient care by leveraging RNAscope technology to address unmet needs in biomarker detection and improve pathology laboratory workflows. These advancements will be highlighted in a seminar at the United States and Canadian Academy of Pathology (USCAP) Annual Meeting taking place from March 22-27 in Boston, MA. Advanced Cell Diagnostics (ACD), a Bio-Techne brand, will be exhibiting and showcasing RNAscope technology at booth #222.

Leading pathologists will describe how they have used RNAscope technology to detect clinically relevant biomarkers, including secreted proteins, point mutations and chromosomal translocations, with the potential to improve performance over existing methods and reduce time to results. The session "RNAscope: Lightning Lunch and Learn" at noon on Tuesday, March 25, will highlight four pathologists describing their work using RNAscope technology:

• Dr. Rohit Mehra, Professor of Pathology at the University of Michigan, will describe TRIM63 mRNA as a surrogate marker in translocation-associated renal cell carcinoma, as an option to traditional DNA FISH.
• Dr. Vikram Deshpande, Professor of Pathology at Beth Israel Deaconess Medical Center, will detail how albumin mRNA can be a superior marker to secreted protein in primary and secondary liver tumors.
• Dr. Brooke Howitt, Associate Professor of Pathology at Stanford University, will present advances in the in situ detection of point mutations in molecularly defined gynecologic tumors.
• Dr. Gregory Bean, Associate Professor of Pathology at Stanford University, will describe the direct detection of mRNA from CRTC1/3::MAML2 translocations, as alternatives to MAML2 FISH, in the identification of mucoepidermoid carcinomas and hidradenomas.

"We've made exciting advancements on in situ hybridization methods enabling novel applications in pathology laboratories," commented Dr. Matt McManus, President of Bio-Techne's Diagnostics and Spatial Biology Segment. "This conference session highlights the frontier of clinical and translational research by leading pathologists using the latest RNAscope technologies for detecting the molecular underpinnings of disease."

For Research Use Only. Not intended for use in diagnostic procedures.

About Bio-Techne

Bio-Techne Corporation (NASDAQ: TECH) is a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities. Bio-Techne products assist scientific investigations into biological processes and the nature and progress of specific diseases. They aid in drug discovery efforts and provide the means for accurate clinical tests and diagnoses. With hundreds of thousands of products in its portfolio, Bio-Techne generated approximately $1.2 billion in net sales in fiscal 2024 and has approximately 3,100 employees worldwide. For more information on Bio-Techne and its brands, please visit http://www.bio-techne.com or follow the Company on social media at Facebook, LinkedIn, Twitter or YouTube.

About Bio-Techne Corporation (NASDAQ: TECH)
Contact: David Clair, Vice President, Investor Relations & Corporate Development
david.clair@bio-techne.com 
612-656-4416

View original content to download multimedia:https://www.prnewswire.com/news-releases/bio-techne-to-highlight-advances-in-the-detection-of-clinically-relevant-biomarkers-using-rnascope-technologies-at-the-2025-uscap-annual-meeting-302407635.html

SOURCE Bio-Techne Corporation

FAQ

What innovations will Bio-Techne (TECH) present at USCAP 2025 regarding RNAscope technology?

Bio-Techne will showcase advancements in RNAscope technology for improved biomarker detection and pathology workflows, featuring presentations on TRIM63 mRNA markers, albumin mRNA detection, point mutation detection, and CRTC1/3::MAML2 translocation detection.

How does Bio-Techne's RNAscope technology improve liver tumor detection?

According to Dr. Deshpande's presentation, RNAscope technology uses albumin mRNA as a superior marker compared to secreted protein for detecting primary and secondary liver tumors.

What are the key applications of TECH's RNAscope technology in gynecologic tumors?

RNAscope technology enables in situ detection of point mutations in molecularly defined gynecologic tumors, as will be presented by Dr. Brooke Howitt at Stanford University.

When and where will Bio-Techne (TECH) present its RNAscope technology at USCAP 2025?

Bio-Techne will present RNAscope technology at booth #222 during USCAP 2025 in Boston (March 22-27), with a special 'Lightning Lunch and Learn' session on March 25.